Fernández-de-Las-Peñas César, Cancela-Cilleruelo Ignacio, Moro-López-Menchero Paloma, Rodríguez-Jiménez Jorge, Gómez-Mayordomo Víctor, Torres-Macho Juan, Pellicer-Valero Oscar J, Martín-Guerrero José D, Hernández-Barrera Valentín, Arendt-Nielsen Lars
Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, Alcorcón, 28922 Madrid, Spain.
Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, 9220 Aalborg, Denmark.
Biomedicines. 2022 Aug 11;10(8):1951. doi: 10.3390/biomedicines10081951.
We compared the prevalence of musculoskeletal post-COVID pain between previously hospitalized COVID-19 survivors infected with the historical, Alpha or Delta SARS-CoV-2 variant. Data about musculoskeletal post-COVID pain were systematically collected through a telephone interview involving 201 patients who had survived the historical variant, 211 who had survived the Alpha variant and 202 who had survived the Delta variant six months after hospital discharge. Participants were recruited from non-vaccinated individuals hospitalized due to SARS-CoV-2 infection in one hospital of Madrid (Spain) during three different waves of the pandemic (historical, Alpha or Delta variant). Hospitalization and clinical data were collected from hospital medical records. In addition, anxiety/depressive levels and sleep quality were also assessed. The prevalence of musculoskeletal post-COVID pain was higher ( = 0.003) in patients infected with the historical variant (47.7%) than in those infected with the Alpha (38.3%) or Delta (41%) variants. A significantly ( = 0.002) higher proportion of individuals infected with the historical variant reported generalized pain (20.5%) when compared with those infected with the other variants. The prevalence of new-onset post-COVID musculoskeletal pain reached 80.1%, 75.2% and 79.5% of patients infected with the historical, Alpha or Delta variants, respectively. No specific risk factors for developing post-COVID pain were identified depending on the SARS-CoV-2 variant. In conclusion, this study found that musculoskeletal post-COVID pain is highly prevalent in COVID-19 survivors six months after hospital discharge, with the highest prevalence and most generalized pain symptoms in individuals infected with the historical variant. Approximately 50% developed "de novo" post-COVID musculoskeletal pain symptoms.
我们比较了感染历史毒株、Alpha或Delta SARS-CoV-2变体的新冠肺炎康复者中肌肉骨骼后遗症疼痛的患病率。通过电话访谈系统收集了有关肌肉骨骼后遗症疼痛的数据，访谈对象包括201名感染历史毒株康复的患者、211名感染Alpha变体康复的患者以及202名感染Delta变体康复的患者，这些患者均在出院六个月后接受访谈。参与者招募自西班牙马德里一家医院因SARS-CoV-2感染住院的未接种疫苗个体，这些个体感染的毒株处于疫情的三个不同阶段（历史毒株、Alpha变体或Delta变体）。住院和临床数据从医院病历中收集。此外，还评估了焦虑/抑郁水平和睡眠质量。感染历史毒株的患者（47.7%）肌肉骨骼后遗症疼痛的患病率高于感染Alpha变体（38.3%）或Delta变体（41%）的患者（P = 0.003）。与感染其他变体的患者相比，感染历史毒株的患者中报告全身疼痛的比例显著更高（20.5%，P = 0.002）。感染历史毒株、Alpha变体或Delta变体的患者中新发肌肉骨骼后遗症疼痛的患病率分别达到80.1%、75.2%和79.5%。未发现根据SARS-CoV-2变体不同而导致后遗症疼痛的特定风险因素。总之，本研究发现，新冠肺炎康复者在出院六个月后肌肉骨骼后遗症疼痛非常普遍，感染历史毒株的个体患病率最高，全身疼痛症状最为常见。约50%的患者出现了“新发”肌肉骨骼后遗症疼痛症状。
